# Prous Institute for Biomedical Research

> Prous Institute for Biomedical Research is a VC fund backing Health Care and Biotechnology. See 3 investments, check sizes, portfolio. Updated Sep 2026.

- Type: VC Fund
- Location: Barcelona, Spain
- Total investments: 3
- Last investment: Sep 2026
- Lead investor: 0%
- Last updated: Sep 2026
- LinkedIn: https://www.linkedin.com/company/prous-institute-for-biomedical-research/
- Website: https://prousresearch.com

Prous Institute for Biomedical Research is a drug discovery company. They provide drugs designed by applying artificial intelligence to digital health applications that allow patients to better manage their diseases, data science innovations are driving a real impact on society. The company specialises in fostering win-win collaboration ties withtop-tier academic institutions, governmental organisations, and research centres committed to transformative research in order to accelerate healthcare innovation.

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $2.4M–$2.9M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 67% |
| Biotechnology | 2 | 67% |
| Medical | 1 | 33% |
| Neuroscience | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 67% |
| Venture - Series Unknown | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Connecta Therapeutics | Connecta Therapeutics is a biotechnology company that develops new treatments for unresolved medical needs of the central nervous system. It focuses on the development of a first-in-class drug for the treatment of fragile X syndrome. | $4.2M | Venture - Series Unknown | Sep 10, 2026 | https://connectatherapeutics.com/ |
| D-Sight | D-Sight is an early treatment for the leading cause of preventable blindness in the working-age population. | $2.4M | Seed | Feb 23, 2026 | https://www.dsight.es/ |
| Connecta Therapeutics | Connecta Therapeutics is a biotechnology company that develops new treatments for unresolved medical needs of the central nervous system. It focuses on the development of a first-in-class drug for the treatment of fragile X syndrome. | $2.9M | Seed | Feb 12, 2024 | https://connectatherapeutics.com/ |

3 of 3 investments shown.

## Co-investors
- [Centre for the Development of Industrial Technology (CDTI)](https://shizune.co/investors/profile/centre-for-the-development-of-industrial-technology-cdti) — VC Fund, 2 deals together
- [Clave Capital](https://shizune.co/investors/profile/clave) — VC Fund, 2 deals together
- [Inveready](https://shizune.co/investors/profile/inveready-technology-investment-group) — VC Fund, 2 deals together
- [Bio Angels Club](https://shizune.co/investors/profile/bio-angels-club) — VC Fund, 1 deal together
- [ENISA](https://shizune.co/investors/profile/enisa-2) — VC Fund, 1 deal together
- [ICF - Institut Català de Finances](https://shizune.co/investors/profile/icf-institut-catal%C3%A0-de-finances) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [ENISA](https://shizune.co/investors/profile/enisa-2) — VC Fund
- [Inveready](https://shizune.co/investors/profile/inveready-technology-investment-group) — VC Fund
- [Angels Capital](https://shizune.co/investors/profile/angels-capital) — VC Fund

## Featured in investor lists
- [Biotechnology VC Funds in Spain](https://shizune.co/investors/biotechnology-vc-funds-spain)

## FAQ

### What does Prous Institute for Biomedical Research invest in?

Prous Institute for Biomedical Research invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Venture - Series Unknown stage. Most of the 3 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Prous Institute for Biomedical Research's check size?

Prous Institute for Biomedical Research typically joins rounds of $2.4M–$2.9M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Prous Institute for Biomedical Research participates in.

### When did Prous Institute for Biomedical Research last invest?

The most recent investment recorded for Prous Institute for Biomedical Research closed in Sep 2026. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co